Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 36 min ago
Peer-reviewedLicence not statedNature Reviews Clinical Oncology

Trial design and end points in hepatocellular carcinoma: an EASL–AASLD–ILCA consensus statement

  • Josep Maria Llovet1,2,3
  • Ezequiel Mauro4
  • Lorenza Rimassa5,6
  • Vincenzo Mazzaferro7,8
  • Matthias Pinter9
  • Robin Kate Kelley10
  • Stephen Lam Chan11
  • Laura Kulik12
  • Anjana A Pillai13
  • Lewis Rowland Roberts14
  • Bruno Sangro15,16
  • Teresa Casanovas17
6 more authors
  • David Edward Kaplan18,19
  • Arndt Vogel20,21
  • Mark M. Yarchoan22
  • Richard S. Finn23
  • Tim Meyer24
  • Amit G. Singal25
25 affiliations
  1. 1Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain. [email protected]
  2. 2Liver Cancer Translational Research Group - Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Liver Unit-Hospital Clínic, Universitat de Barcelona, Barcelona, Spain. [email protected]
  3. 3Mount Sinai Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. [email protected]
  4. 4Liver Cancer Translational Research Group - Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Liver Unit-Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
  5. 5Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
  6. 6Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy
  7. 7Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
  8. 8Department of Surgery, HPB Surgery and Liver Transplantation, Instituto Nazionale Tumori IRCCS, Milan, Italy
  9. 9Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
  10. 10Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
  11. 11State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China
  12. 12Department of Medicine (Gastroenterology and Hepatology), Northwestern University Feinberg School of Medicine, Chicago, IL, USA
  13. 13Department of Internal Medicine, University of Chicago, Chicago, IL, USA
  14. 14Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA
  15. 15Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain
  16. 16Liver Unit and HPB Oncology Area, Clinica Universidad de Navarra, Madrid, Spain
  17. 17European Liver Patients' Association (ELPA), Barcelona, Spain
  18. 18Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
  19. 19The Corporal Michael J. Crescenz Veterans Administration Medical Center, Philadelphia, PA, USA
  20. 20Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
  21. 21Division of Gastroenterology and Hepatology, Toronto General Hospital, Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada
  22. 22The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA
  23. 23Royal Free Hospital and UCL Cancer Institute, University College London, London, UK
  24. 24Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
  25. 25Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA
Open at sourcePDFDOICite

Related

  1. Adjuvant and Perioperative Systemic Therapy for Resectable Hepatocellular Carcinoma: Evidence, Biological Rationale, and Trial Design
    Xin Xin, Ruoyu Miao
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  2. DUBHE-H-308 study protocol: rationale and adaptive design of a randomized, open-label, seamless phaseII/III trial of iparomlimab and tuvonralimab (QL1706)-based regimens versus sintilimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma
    Fan Yang, Weikang Tao, Zihang Zhong +3
    Future OncologyPeer-reviewedLicence not statedFull textGeneral medicinePMC
  3. Comment on Rapone et al. Consensus Statement on Full-Arch Implant Rehabilitations: Evidence-Based Recommendations from the Italian Consensus Conference. J. Clin. Med. 2026, 15, 3695
    Federico Tirone
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0General medicineCrossref
  4. The European Association of Neuro-Oncology consensus statement on radiation necrosis
    Johnny Duerinck, Martin Van Den Bent, Petter Brandal +17
    Neuro-OncologyPeer-reviewedPublisher termsFull text5 citedOncologyPMC
  5. Genetic testing in pituitary adenomas: a Pituitary Society International Consensus Statement
    Sunita de Sousa, Cynthia Andoniadou, Adrian Daly +21
    Nature Reviews EndocrinologyPeer-reviewedLicence not statedFull text2 citedGeneral biologyEndocrinology & metabolismHAL

Cite

BibTeXRIS
BibTeX
@article{llovet2026trial,
  title = {{Trial design and end points in hepatocellular carcinoma: an EASL–AASLD–ILCA consensus statement}},
  author = {Josep Maria Llovet and Ezequiel Mauro and Lorenza Rimassa and Vincenzo Mazzaferro and Matthias Pinter and Robin Kate Kelley and Stephen Lam Chan and Laura Kulik and Anjana A Pillai and Lewis Rowland Roberts and Bruno Sangro and Teresa Casanovas and David Edward Kaplan and Arndt Vogel and Mark M. Yarchoan and Richard S. Finn and Tim Meyer and Amit G. Singal},
  journal = {Nature Reviews Clinical Oncology},
  year = {2026},
  month = jun,
  doi = {10.1038/s41571-026-01160-z},
  url = {https://doi.org/10.1038/s41571-026-01160-z},
}
RIS
TY  - JOUR
TI  - Trial design and end points in hepatocellular carcinoma: an EASL–AASLD–ILCA consensus statement
AU  - Josep Maria Llovet
AU  - Ezequiel Mauro
AU  - Lorenza Rimassa
AU  - Vincenzo Mazzaferro
AU  - Matthias Pinter
AU  - Robin Kate Kelley
AU  - Stephen Lam Chan
AU  - Laura Kulik
AU  - Anjana A Pillai
AU  - Lewis Rowland Roberts
AU  - Bruno Sangro
AU  - Teresa Casanovas
AU  - David Edward Kaplan
AU  - Arndt Vogel
AU  - Mark M. Yarchoan
AU  - Richard S. Finn
AU  - Tim Meyer
AU  - Amit G. Singal
PY  - 2026
DA  - 2026/06/10
JO  - Nature Reviews Clinical Oncology
DO  - 10.1038/s41571-026-01160-z
UR  - https://doi.org/10.1038/s41571-026-01160-z
SN  - 1759-4774
SN  - 1759-4782
ER  -